Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Strong Long who wrote (1794)	3/29/2016 8:18:00 PM
From: mokelumne river	Read Replies (1) of 2026

SL, the company played up Fis and that was the assumed reason that Denner took the plunge. So I also think the market is over reacting to the Fis news, but it is understandable the way Fis was promoted. If you assume the Vitaros overseas revenues projected in the Taglich report for 2020, 62 cents a share is attractive: An overseas target erectile dysfunction (ED) patient population of nine million underlies substantial Vitaros revenue potential. Modest penetration of Vitaros’ overseas target markets could, in our view, generate $75 million in revenue by 2020. A Vitaros launch in the US would lend considerable upside to that forecast. And again, the above does not include a US launch. So I am more than a cup is half full in my outlook.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next